RAI-refractory Diffrentiated Thyroid Cancer | Primary Research (KOL's Insight) | Market Intelligence | Epidemiology & Market Forecast-2035

Refractory thyroid cancer caused by radioactive iodine (RAI) is a rare disease with an incidence of 4-5 cases per year per million people. Patients who are older, have large metastases, have anaplastic thyroid cancer, or have tumors with high levels of 18-fluorodeoxyglucose on PET/CT are more likely to develop radioiodine resistance. An estimated 4-5 cases/year/million people are diagnosed with thyroid cancer that is radioiodine (RAI)-refractory. The most prevalent endocrine system malignancy, thyroid cancer accounts for about 2.1% of all cancer diagnoses worldwide. Patients with radioactive iodine (RAI)-differentiated thyroid cancer (DTC), a serious condition with a poor prognosis, had no real treatment options up until recently.

Description

With an incidence of 4-5 cases per year/million people, radioactive iodine (RAI) - Refractory thyroid cancer is a rare disease. Patients who are older, have large metastases, have anaplastic thyroid cancer, or have tumors with elevated 18-fluorodeoxyglucose levels on PET/CT are more likely to develop radioiodine resistance. These patients have a less than 10% 10-year survival rate. Even though differentiated thyroid cancer (DTC) is highly prevalent and on the rise, only a small percentage of patients-less than 10% of those with clinical disease-develop distant metastases. Radioactive iodine (RAI) resistance will develop in two-thirds of these patients, which translates to 4-5 new cases per year/million. Three to five years are to be expected after the diagnosis of advanced radioactive iodine disease. Surgery, radioactive iodine, and thyroid-stimulating hormone (TSH) suppression are frequently used to treat differentiated thyroid cancer (DTC). However, during follow-up, 15% of patients experienced local recurrence and/or distant metastases, and approximately two-thirds of these patients developed resistance to RR-DTC and had a poor prognosis.

RAI-refractory Differentiated Thyroid Cancer (Epidemiology)

An estimated 4-5 cases/year/million people are diagnosed with thyroid cancer that is radioiodine (RAI)-refractory. The most prevalent endocrine system malignancy, thyroid cancer accounts for about 2.1% of all cancer diagnoses worldwide. It represented 3.8% of all new cancer cases identified in the United States (US) in 2014 and ranked as the 9th most frequent malignancy in terms of incidence as a whole. This is viewed everywhere. Next, we discuss the size of the increase, potential contributing factors, and mitigation measures. According to data available as of October 11, 2015, the most recent year for which figures are available, there were roughly 57,000 new cases of thyroid cancer in the United States in 2017. Thyroid cancer accounted for about 35% of all cancer diagnoses that year. By 2030, thyroid cancer is anticipated to overtake leukemia as the fourth most common cancer in the United States if current trends hold. Each country has a different incidence of thyroid cancer; South Korea has the highest rate (111/100,000). Infection rates do not follow any predictable trends; for instance, thyroid cancer rates are high in some nations but low in those that are close by. Aside from Brazil and China, other nations with recent increases in infection rates include India and South Africa. In the US, women have a DTC incidence rate that is three times higher than that of men (7.7/100,000 vs.22.3/100,000). This relationship is reflected in global comparisons, which show a global age-standardized incidence of 6/10.000 women and 1/19,000 men. Thyroid cancer is currently diagnosed at an average age of 49 for women and 54 for men, which is younger than the average age for most other cancers. Asians, Hispanics, and non-Hispanic African Americans had the highest incidence of DTC in the United States, which was then followed by non-Hispanic whites. Cancer is associated with an increased risk of death (odds ratio [OR] 4/1, confidence interval [CI] 1/7 to 9/1 in one study), but the underlying genetics of this observation are unclear. It typically takes three first-degree relatives to have true familial thyroid cancer, which is uncommon.

RAI-refractory Differentiated Thyroid Cancer -Current Market Size & Forecast Trends

The market for radioactive iodine (RAI)-refractory differentiated thyroid cancer (RAIR-DTC) is currently part of the broader differentiated thyroid cancer treatment landscape. The global differentiated thyroid cancer treatment market is estimated to be valued at approximately USD 502.5 million in 2024, with projections indicating growth to around USD 2.09 billion by 2031, reflecting a compound annual growth rate (CAGR) of 22.6% during this period. Specifically, the RAI-refractory segment faces challenges due to its poor prognosis and limited treatment options, with survival rates significantly lower than those for RAI-responsive cases. As awareness of RAIR-DTC increases and new targeted therapies are developed, including kinase inhibitors and immunotherapies, the market for RAI-refractory differentiated thyroid cancer is expected to expand substantially through 2035, driven by ongoing research and advancements in treatment strategies.

For patients with radioactive iodine (RAI)-differentiated thyroid cancer (DTC), a serious condition with a poor prognosis, there have not previously been any truly effective treatment options. The targeted multikinase inhibitor sorafenib was authorized for these patients in November 2013 as a result of a notable increase in progression-free survival versus placebo. Phase II and III trials are looking into a number of other targeted medications, including lenvatinib. Practitioners must make crucial choices as these new treatment options emerge regarding which patients qualify for systemic therapy and when to begin treatment. Given that patients may experience prolonged asymptomatic periods, tumor size and growth rate are crucial factors to take into account when making this decision. To enhance the effectiveness of treatment, side effects must be actively managed. Tyrosine kinase inhibitors in particular have been developed as new treatments for follicular cell-derived thyroid cancer in recent years. Recent approvals for differentiated thyroid cancer (DTC) treatment include lentinib, sorafenib, and cabozantinib, while approvals for tropomyosin receptor-neuronal kinase-fused thyroid cancer treatment include larotrectinib and entrectinib. The goal of ongoing RAI trials is to find medications that can replenish radioiodine by using a differentiation regimen (vemurafenib, dabrafenib, and trametinib), combination therapy, or both. These therapies are based on the tumor's molecular signature. Drug resistance still accounts for a significant portion of treatment failure, despite how targeted therapy has altered prognosis and treatment approaches.

Report Highlights

RAI-refractory Differentiated Thyroid Cancer - Current Market Trends

RAI-refractory Differentiated Thyroid Cancer - Current & Forecasted Cases across the G8 Countries

RAI-refractory Differentiated Thyroid Cancer - Market Opportunities and Sales Potential for Agents

RAI-refractory Differentiated Thyroid Cancer - Patient-based Market Forecast to 2035

RAI-refractory Differentiated Thyroid Cancer - Untapped Business Opportunities

RAI-refractory Differentiated Thyroid Cancer - Product Positioning Vis-a-vis Competitors' Products

RAI-refractory Differentiated Thyroid Cancer - KOLs Insight